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Re-thinking the preclinical development of GBM therapeutics
Érika Cosset, Sara M. Weis and David A. Cheresh
Glioblastoma multiforme (GBM) remains one of 
the most incurable cancers.  Although the genomic era 
has produced massive quantities of data in an attempt to 
characterize its molecular drivers[1, 2], these advances 
have yet to be effectively translated into clinical impact. 
In fact, several studies have identified the presence of all 
three GBM molecular subtypes within a single patient 
tumor[3, 4], illustrating the complexity of designing 
personalized medicine approaches.  In addition to the 
strong intra/inter-tumoral heterogeneity, the inability of 
targeted therapies to achieve long-term remissions is likely 
a function of multiple complicating factors, including the 
presence of glioblastoma stem cells, redundant signaling 
pathways, the unique infiltrative nature of GBM cells, 
and difficulties associated with drug delivery across the 
blood-brain-barrier.  New strategies to match patients to 
molecularly targeted therapies will also need to overcome 
these challenges imposed by the challenging GBM 
microenvironment within the brain.  
The clinical development and testing of the αv 
integrin antagonist cilengitide provides an interesting 
case study to show how a personalized medicine 
approach may be able to resurrect a therapeutic that 
failed to provide a survival benefit in an “unselected” 
GBM patient population.  Cilengitide (EMD 121974), is 
a cyclic peptide designed to block the function of αvβ3 
and αvβ5 integrins that had been implicated as key drivers 
of tumor angiogenesis and glioblastoma progression[5]. 
While higher levels of αvβ3 were associated with a 
modest survival benefit for cilengitide, αvβ3 expression 
status alone did not correlate with patient outcome[6]. 
Although a number of patients showed an unexplained 
high sensitivity to the drug and achieved long-term stable 
disease, cilengitide failed to meet its overall survival 
endpoints in phase II-III clinical trials and its clinical 
development was halted[7].  Considering the wealth of 
studies pointing to integrin αvβ3 as a key driver of GBM 
progression, we and others involved in the preclinical 
testing of integrin antagonists were disappointed and 
perplexed when cilengitide did not provide a more 
significant benefit in man.
We therefore reconsidered whether all GBM tumors 
are equally addicted to integrin αvβ3 during progression. 
Remarkably, we discovered that sensitivity to αvβ3 
blockade could not simply be predicted by high αvβ3 
expression, but rather on a state of addiction to the high-
affinity glucose transporter, Glut3, that provides tumors 
with a critical glucose-uptake advantage in the nutrient-
poor environment of the brain[8]. Mechanistically, we 
identified integrin αvβ3 signaling through PAK4 and 
YAP/TAZ as being necessary and sufficient to promote 
the expression of Glut3.  Accordingly, individual patient-
derived GBM tumors that showed sensitivity to Glut3 
knockdown showed sensitivity to not only cilengitide and 
LM609 (a monoclonal antibody antagonist of αvβ3), but 
also to drugs that inhibit PAK4 and YAP/TAZ.  
Furthermore, we identified a genetic signature 
capable of predicting which GBM tumors would show 
this Glut3-addicted phenotype. In particular, we found 
that GBM tumors with markers defining the proneural 
and classical molecular subtypes were addicted to αvβ3/
Glut3.  In contrast, tumors with markers defining the 
mesenchymal subtype were not addicted, even when 
they displayed high expression of both αvβ3 and Glut3. 
This distinction highlights how functionally relevant 
markers can be incorporated into molecular classification 
approaches to predict which subsets of patients may 
respond to a given drug, providing important inclusion 
criteria for clinical trials.  Such an analysis to account for 
durable responses in individual patients will provide a 
framework for setting up new molecularly defined clinical 
trials. 
Our study also highlights the value of patient-
derived gliomaspheres to reflect GBM heterogeneity and 
addiction status. Indeed, we found the established GBM 
cell lines U87MG, LN229, and LN18 to be highly sensitive 
to agents targeting αvβ3/PAK4-YAP/TAZ signaling axis, 
whereas only a subpopulation of patient-derived GBM 
stem cell models showed sensitivity.  Although the nearly 
universal effect of cilengitide on established GBM cell 
lines in vitro and in vivo generated great enthusiasm for its 
clinical development, only some patients responded to this 
therapy.  In fact, we observed a paradoxical enhancement 
of viability for several of the “non-addicted” GBM stem 
cells treated with αvβ3 antagonists.  The highly variable 
response to cilengitide among our panel of patient-derived 
GBM stem cell models may account for why this drug 
failed to prolong overall survival in a non-selected GBM 
patient population.  Although our sample size is relatively 
limited, we predict that less than a quarter of GBM 
tumors would show sensitivity to cilengitide and that 
progression may even be accelerated in certain patients. 
Going forward, the challenge will be to develop rapid and 
feasible genetic or molecular screens to identify αvβ3/
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Glut3 addiction in living patients, and to optimize a CLIA-
certified screening process to reliably predict responders.  
Taken together, our recent study highlights new 
opportunities to exploit the analysis of “big data” to 
achieve advances in precision medicine and reinforces 
the importance of profiling individual tumors.  Using 
cilengitide as an example, we suggest that other “failed” 
drugs may be reconsidered using patient-derived models, 
allowing them to advance to a more defined style of GBM 
clinical trial that relies on molecularly-defined inclusion/
exclusion criteria to identify a potentially small population 
of responders.
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